Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic...

Area of Science:

• Nephrology
• Molecular Biology
• Pathogenesis of Diabetic Nephropathy

Background:

• Connective tissue growth factor (CCN2) is a profibrotic protein implicated in diabetic nephropathy (DN).
• CCN2 signaling is mediated by tropomyosin receptor kinase A (TrkA), which is expressed at low levels in normal kidneys but elevated in other nephropathies.
• The role of TrkA in DN pathogenesis remains unexplored.

Purpose of the Study:

• To investigate the expression and activation of TrkA in diabetic kidneys.
• To elucidate the molecular mechanisms underlying TrkA activation in DN.
• To explore the potential of anti-TrkA therapy for DN.

Main Methods:

• Assessed de novo TrkA expression in human and murine DN models.
• Investigated TrkA activation mechanisms involving hypoxia (ischemia-reperfusion injury, in vitro hypoxia models).
• Examined the effects of hyperglycemia on TrkA phosphorylation and downstream signaling (ERK1/2, Snail1) in various renal cell types using siRNA for TrkA and CCN2.

Main Results:

• Demonstrated de novo TrkA expression in human and murine DN kidneys.
• Identified hypoxia as a key factor in TrkA activation.
• Showed hyperglycemia induces TrkA phosphorylation in mesangial cells, tubular epithelial cells, and podocytes.
• Confirmed that hyperglycemia-induced ERK1/2 and Snail1 phosphorylation is dependent on TrkA and CCN2.

Conclusions:

• TrkA is activated in diabetic kidneys, suggesting a novel role in DN pathogenesis.
• Hypoxia and hyperglycemia are implicated in TrkA activation pathways in DN.
• Targeting TrkA represents a potential therapeutic strategy for treating diabetic nephropathy.